Are you Qurr-ious? MYOS Rens Technology Inc. Launches Qurr Product Line Powered by Fortetropin®, an All-Natural Ingredient Clinically Proven to Increase Muscle Size and Mass

News provided by

Mar 13, 2017, 06:00 ET

CEDAR KNOLLS, N.J., March 13, 2017 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ : MYOS ), today announced the launch of its much anticipated Qurr product line, which is available for both individual product purchase and subscription orders from the Qurr.com e-commerce site and educational portal. Qurr products, available in delicious powders, puddings and shakes, contain MYOS' proprietary ingredient Fortetropin^®, which is clinically shown to reduce serum myostatin levels and increase lean muscle size and mass.

"Muscle is critical to our overall well-being and we are thrilled to offer products developed to build healthy muscles which provide a foundation for full-body health and overall healthy living," said Joseph Mannello, CEO of MYOS. "Consumers simply take one packet a day in conjunction with resistance training, and within three months can see increases in lean muscle mass."

Qurr products are designed for customer convenience and maximum results. Broken up into easily transported packets and available in four flavors, Qurr products target three distinct demographics:

Qurr Well, which supports healthy aging by increasing lean muscle
Qurr Toned, for promoting healthy muscle which can lead to a beautiful lean and toned body
Qurr Strong, for athletes hoping to reach their most ambitious training goals

Qurr products are powered by MYOS' proprietary ingredient, Fortetropin^®, which has been clinically shown to reduce serum myostatin levels and increase lean muscle size and mass. Fortetropin^® is a bioactive proteo-lipid complex containing various proteins and other bioactive molecules isolated from fertilized egg yolk using a patented process that preserves the biological integrity and bioactivity of the mixture. Fortetropin^® is the first safe and all-natural myostatin reducing product available, with no adverse events reported during any MYOS clinical studies.

"While MYOS has always offered trusted products consumers can rely on, our product lines and science have continued to evolve," said Mannello. "Qurr is the natural outcome of that process. Furthermore, we take our commitment to designing muscle health products seriously and have constructed our website as a wellness destination. Qurr.com will provide muscle health education through articles, blogs, personal trainer insights, resource tools, current news and breakthroughs, in addition to product ordering information."

Qurr products are low calorie, naturally soy free and non-GMO, with a recommended daily dose of 6.6 grams of Fortetropin^®. Packages start at $129.99 per month with additional savings for monthly subscriptions or larger quantities. For more information or to purchase Qurr, please visit www.qurr.com.

About MYOS RENS Technology Inc.

MYOS RENS Technology (MYOS), "The Muscle Company™", is a Cedar Knolls, NJ-based biotherapeutics and bionutrition company focused on developing products that improve muscle health and performance and bringing them to market. MYOS is the owner of Fortetropin^®, the world's first clinically demonstrated myostatin reducer. Myostatin is a natural regulatory protein, which inhibits muscle growth and recovery. Fortetropin^® is manufactured to optimize biological activity, which MYOS believes has the potential to redefine existing standards of physical health and wellness enhancement.

Forward-Looking Statements

Any statements in this release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the ability to create new products through research and development, the successful launch of our products, including Qurr products, the success of our research and development, the results of the clinical evaluation of Fortetropin^® and its effects, the ability to enter into partnership opportunities, the ability to generate the forecasted revenue stream and cash flow from sales of our products, the ability to achieve a sustainable, profitable business, the effect of economic conditions, the ability to protect our intellectual property rights, competition from other providers and products, the continued listing of our securities on the Nasdaq Stock Market, risks in product development, our ability to raise capital to fund continuing operations, and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

These statements have not been evaluated by the Food and Drug Administration. Our products are not intended to diagnose, treat, cure or prevent any disease.

SOURCE MYOS RENS Technology Inc.